Ruben Iglesias Gomez

Ruben Iglesias Gomez

Auto-generated profile, based on publicly available information

Ruben Iglesias Gomez

Pharmacy department Hospital Universitari i Politècnic La Fe Avinguda de Fernando Abril Martorell, Valencia Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2021 in European Journal of Hospital Pharmacy
Verified
Journal Article
Open access
PDF file
RGRubén Iglesias Gómez
Rubén Iglesias Gómez
RMRaúl Méndez
Raúl Méndez
TPTomás Palanques-Pastor
Tomás Palanques-Pastor
OBOctavio Ballesta-López
Octavio Ballesta-López
CAConxa Borrás Almenar
Conxa Borrás Almenar
JAJosé Luis Poveda Andrés
José Luis Poveda Andrés
Objectives To analyse the effectiveness and safety of baricitinib for severe COVID-19 in cytokine storm syndrome based on its potential role as an anti-inflammatory immunomodulator and inhibitor of viral endocytosis. Methods This was an observational retrospective study of hospitalised patients treated with baricitinib for severe COVID-19. Outcomes were clinical improvement on an ordinal scale of 1–8 on day 1 of baricitinib compared with day 14 (where 8=death and 1=not hospitalised with no limitations of activities), overall survival, time to recovery since baricitinib treatment started (days until hospital discharge) and laboratory parameters related to COVID-19 poor prognosis. Adverse events related to baricitinib during the admission period were also reported. Results Forty-three patients (70% men, mean age 70 years (IQR 54–79)) treated with baricitinib daily for 6 days (IQR 5–7) were included. Thirty-six patients were treated with corticosteroids (84%). Clinical improvement was 3 points (IQR 1–4) in patients on an ordinal scale of 4–6, overall survival was 100% at day 30 and day 60 with a mean time to recovery of 12 days (IQR 9–25) from start of baricitinib treatment. No adverse events of interest were found and all poor prognosis risk factors improved at day 14: interleukin-6, C-reactive protein, ferritin, lymphocytes, platelets and D-dimers. Conclusions Patients treated with baricitinib for severe COVID-19 showed improvements in clinical and analytical values without relevant adverse events and 100% overall survival. Clinical randomised trials are needed to confirm the clinical benefit of baricitinib.

31 May 2022 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
RGRuben Iglesias Gomez
Ruben Iglesias Gomez
INIsabel Font Noguera
Isabel Font Noguera
MBMarta Correa Ballester
Marta Correa Ballester
MCMaria Jose Ruiz Caldes
Maria Jose Ruiz Caldes
JAJose Luis Poveda Andres
Jose Luis Poveda Andres